费城办事处讯：嘉因生物 Exegenesis Bio 是一家快速发展的全球基因治疗公司，在此很高兴地宣布，美国食品药品监督管理局 (FDA) 已经批准了 EXG102-031 的研究性新药 (IND) 申请，这种基于腺相关病毒 (rAAV) 的重组基因疗法正在用于治疗新生血管性年龄相关性黄斑变性 (nAMD)，这是全球严重视力丧失和不可逆失明的主要原因。点击这里读取完整的新闻稿

PHILADELPHIA--(BUSINESS WIRE) -- Exegenesis Bio, a rapidly growing global gene therapy company is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for EXG102-031, a recombinant adeno-associated virus (rAAV) based gene therapy that is being studied for the treatment of neovascular Age Related Macular Degeneration (nAMD), the leading cause of severe vision loss and irreversible blindness worldwide. Read full press release

费城办事处，2021 年 9 月 15 日讯：嘉因生物 Exegenesis Bio 是一家快速发展的全球基因治疗公司，致力于开发针对眼科、中枢神经系统和肝脏疾病的创新基因药物，在此很高兴地宣布任命 Mahen Gundecha 为首席商务官。点击这里读取完整的新闻稿

PHILADELPHIA, PA, September 15, 2021 (BUSINESS WIRE) – Exegenesis Bio, a rapidly growing global gene therapy company, developing innovative genetic medicines for eye, CNS and liver-directed diseases is pleased to announce the appointment of Mahen Gundecha as Chief Business Officer. Read full press release

费城办事处，2021 年 9 月 8 日讯：嘉因生物 Exegenesis Bio 是一家快速发展的全球基因治疗公司，致力于开发针对眼科、中枢神经系统和肝脏疾病的创新基因药物，在此很高兴地宣布其下一阶段的业务扩张，包括计划在未来 12 个月内将规模扩大一倍，并在费城开设业务办事处，在波士顿开设研究业务，并在新加坡开设区域办事处。点击这里读取完整的新闻稿

PHILADELPHIA, PA, Sep 8, 2021 (BUSINESS WIRE) – Exegenesis Bio, a rapidly growing global gene therapy company, developing innovative genetic medicines for eye, CNS and liver-directed diseases is pleased to announce the next phase of its business expansion, including plans to double in size during the next 12 months and opening of business offices in Philadelphia, research operations in Boston and a regional office in Singapore. Read full press release

费城办事处，2021 年 6 月 23 日讯：嘉因生物 Exegenesis Bio 是一家快速发展的全球基因治疗公司，致力于开发针对眼科、中枢神经系统和肝脏疾病的创新基因药物，在此很高兴地宣布完成其 B++ 系列融资，本轮风险投资超过 5000 万美元。本轮融资由高瓴资本领投，现有投资者LYFE Capital和BioTrack Capital，以及新投资者淡马锡控股、CPE和Lake Bleu Capital。点击这里读取完整的新闻稿

PHILADELPHIA, PA, June 23, 2021 (BUSINESS WIRE) – Exegenesis Bio, a rapidly growing global gene therapy company, developing innovative genetic medicines for eye, CNS and liver-directed diseases is pleased to announce the completion of its series B++ financing, raising over $50 M of venture investments in this round. The round was led by Hillhouse Capital Group and included existing investors LYFE Capital and BioTrack Capital, as well as new investors Temasek Holdings, CPE and Lake Bleu Capital. Read full press release